98%
921
2 minutes
20
Susceptibility to cervical cancer has been associated with Toll-like receptors (TLRs), which is an important component of innate immunity. According to previous studies, polymorphisms in TLRs genes can affect immune response pathways and lead to the development of cervical cancer. The present study aims to evaluate the functionality of polymorphisms in TLR1, TLR4 and TLR9 genes and their associations with cervical cancer. To identify the functionality of polymorphisms, we used the following tools: MUpro, ChimeraX, SNP2TFBS and GTEx. A case-control study including 57 cases (11 High-grade Intraepithelial Lesion - HSIL and 46 cervical cancer) and 67 clinically healthy controls was conducted in the Brazilian population. Polymorphisms genotyping was performed by real-time PCR, using TaqMan probes, using the allelic discrimination method. Bioinformatics prediction showed that the TLR1 rs4833095 [NM_003263.4 (TLR1):c.743T>C (p.Asn248Ser)] and TLR4 rs4986790 [NM_138554.5 (TLR4):c.896A>G (p.Asp299Gly)] polymorphisms alter the structure and stability of their respective proteins. TLR9 rs187084 [NM_017442.3(TLR9):c.-1486A>G] polymorphism seems to affect the THAP1 binding site and modify gene expression. In the case-control study, the c.743TC heterozygous genotype of the rs4833095 SNP in the TLR1 gene was associated with an increased risk for HSIL/cervical cancer. No association of TLR4 rs4986790 and TLR9 rs187084 SNPs with HSIL/cervical cancer was found in the studied population. Allelic combination CAG (rs4833095/ rs4986790/ rs187084) increased the risk of cervical cancer. In conclusion, the present study identified that polymorphisms in TLRs genes can affect the phenotype of their respective genes and contribute to the development of HSIL or cervical cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cancergen.2024.10.001 | DOI Listing |
Pol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.
Epidemiol Serv Saude
September 2025
Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
Objectives: To assess the time taken to diagnose cervical cancer in Brazil and identify associated sociodemographic and clinical factors in the period 2016-2020.
Methods: This was a cross-sectional study of cervical neoplasms diagnosed between 2016 and 2020, using data collected from the Hospital Cancer Registry. The logistic regression model was applied to calculate odds ratios (OR) and 95% confidence intervals (95%CI).
Cien Saude Colet
August 2025
Instituto de Medicina Social Hesio Cordeiro, Universidade do Estado do Rio de Janeiro. R. São Francisco Xavier 524, Maracanã. 20550-900 Rio de Janeiro RJ Brasil.
In this article an analysis of the preventive campaigns against cervical cancer (CC) and human papillomavirus (HPV) vaccination developed by the National Cancer Institute (INCA) of the Ministry of Health was conducted, in addition to some campaigns produced by non-governmental organizations and private institutions, from 2014 to 2020. From a socio-anthropological point of view, the objective was to understand how these health technologies trigger and produce gender representations. Seven categories of analysis were developed ("Generationality of care", "Schooling", "Childhood and Youth", "Gamification", "Health risk", "Men's health" and "Neutrality") that permitted discussion of the themes that emerged in graphic pieces.
View Article and Find Full Text PDFJ Natl Cancer Inst
September 2025
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: While screening for cervical, colorectal, and lung cancers reduce cancer-specific mortality, the full benefits of screening are only realized when coupled with timely care across the subsequent "screening continuum" steps, including surveillance (results warranting frequent monitoring), diagnostic evaluation (results that require additional testing), and treatment (detected cancers). Our goal was to describe the proportion of individuals receiving timely cervical, colorectal, and lung cancer care at each step in the screening continuum.
Methods: This retrospective cohort study used data from the 10 health care settings that participate in the Population-based Research to Optimize the Screening Process (PROSPR II) consortium and included individuals who were eligible for a step along the cancer screening continuum in 2018.
PLOS Glob Public Health
September 2025
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States of America.
To compare HPV vaccination knowledge and non-adherence rates to cervical cancer screening in a nationally representative sample of American women before and following the COVID-19 pandemic, female participants aged 21-65 years from the National Cancer Institute Health Information National Trends Survey 2019 and 2022 were included. Adherence to cervical cancer screening was assessed based on the timing of their last Papanicolaou (PAP) smear, with participants classified as non-adherent to cervical cancer guidelines if their last PAP smear was > 3 years. Further, participants were asked about their knowledge of the HPV vaccine and were categorized as unaware if they had not heard of it before.
View Article and Find Full Text PDF